A study in twins found that even a single traumatic brain injury at any age was associated with worse cognitive function in later life, independent of genes and environmental factors.
Co-authors Eric Elbogen, PhD, professor of psychiatry and behavioral sciences, and Nico Verykoukis, a retired clinical social worker with 29 years of experience, debunk the common myth that most perpetrators of violent crime are mentally ill.
Duke University School of Medicine’s Black Employee Resource Group, ME², aims to foster a community focused on networking, professional development, and leadership opportunities for Black staff.
Speaking to media in a virtual briefing, infectious disease specialist Dr. Cameron Wolfe and David Montefiori, Ph.D., director of the Duke Human Vaccine Institute, said booster shots continue to be effective for those Americans who routinely get them.
The Office of Biomedical Graduation Education honored exceptional second-year international PhD students with nine prestigious International Chancellor’s Scholarships.
Congratulations to the students from the Duke University School of Medicine who graduated this summer from health professions and biomedical PhD programs.
A formulation for intravenous nutrition that includes four lipid sources, including fish oil, reduced hospitalizations and urinary tract infections among pediatric patients at Duke Children’s Hospital.
State, federal, and international health and human services leaders discussed the current challenges and initiatives relating to behavior and mental health. The panel shared strategies, policies, and innovative thinking in understanding and tackling mental health which may be the nation's newest pandemic.
As genetic and genomic research continues to rapidly evolve, scientists and researchers are gaining a deeper understanding of the role of genetics in health and disease.
A man-made antibody successfully prevented organ rejection when tested in primates that had undergone a kidney transplant, Duke Health researchers report. The finding clears the way for the new monoclonal antibody to move forward in human clinical trials.